These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 7636196

  • 1. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI, Nelson H, Thibault C.
    J Immunol; 1995 Aug 01; 155(3):1296-303. PubMed ID: 7636196
    [Abstract] [Full Text] [Related]

  • 2. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
    Penna C, Dean PA, Nelson H.
    Cancer Res; 1994 May 15; 54(10):2738-43. PubMed ID: 8168104
    [Abstract] [Full Text] [Related]

  • 3. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
    Hirsch R, Archibald J, Gress RE.
    J Immunol; 1991 Oct 01; 147(7):2088-93. PubMed ID: 1833451
    [Abstract] [Full Text] [Related]

  • 4. Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application.
    Chapoval AI, Nelson H, Thibault C, Penna C, Dean P.
    J Hematother; 1995 Dec 01; 4(6):571-7. PubMed ID: 8846018
    [Abstract] [Full Text] [Related]

  • 5. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A, Stevenson GT, Glennie MJ.
    J Immunol; 1991 Jul 01; 147(1):60-9. PubMed ID: 1675655
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies.
    Reid I, Lundy J, Donohue JH.
    J Immunol; 1992 Apr 15; 148(8):2630-5. PubMed ID: 1532818
    [Abstract] [Full Text] [Related]

  • 7. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY.
    J Immunol; 1994 Mar 01; 152(5):2385-92. PubMed ID: 8133049
    [Abstract] [Full Text] [Related]

  • 8. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
    Thibault C, Nelson H, Chapoval AI.
    Int J Cancer; 1996 Jul 17; 67(2):232-7. PubMed ID: 8760593
    [Abstract] [Full Text] [Related]

  • 9. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
    Ledbetter JA, June CH, Martin PJ, Spooner CE, Hansen JA, Meier KE.
    J Immunol; 1986 Jun 01; 136(11):3945-52. PubMed ID: 3084650
    [Abstract] [Full Text] [Related]

  • 10. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
    Blazar BR, Jenkins MK, Taylor PA, White J, Panoskaltsis-Mortari A, Korngold R, Vallera DA.
    J Immunol; 1997 Dec 15; 159(12):5821-33. PubMed ID: 9550378
    [Abstract] [Full Text] [Related]

  • 11. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
    Nelson H, Ramsey PS, Kerr LA, McKean DJ, Donohue JH.
    J Immunol; 1990 Nov 15; 145(10):3507-15. PubMed ID: 1700013
    [Abstract] [Full Text] [Related]

  • 12. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.
    Cancer Res; 2002 Oct 15; 62(20):5785-91. PubMed ID: 12384539
    [Abstract] [Full Text] [Related]

  • 13. Activation and preferential expansion of rat cytotoxic (CD8) T cells in vitro and in vivo with a bispecific (anti-TCR alpha/beta x anti-CD2) F(ab')2 antibody.
    Tutt AL, Reid R, Wilkins BS, Glennie MJ.
    J Immunol; 1995 Sep 15; 155(6):2960-71. PubMed ID: 7673714
    [Abstract] [Full Text] [Related]

  • 14. CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.
    Molema G, Tervaert JW, Kroesen BJ, Helfrich W, Meijer DK, de Leij LF.
    Br J Cancer; 2000 Jan 15; 82(2):472-9. PubMed ID: 10646907
    [Abstract] [Full Text] [Related]

  • 15. Target cell-induced T cell activation with bi- and trispecific antibody fragments.
    Jung G, Freimann U, Von Marschall Z, Reisfeld RA, Wilmanns W.
    Eur J Immunol; 1991 Oct 15; 21(10):2431-5. PubMed ID: 1655465
    [Abstract] [Full Text] [Related]

  • 16. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.
    Kahn M, Sugawara H, McGowan P, Okuno K, Nagoya S, Hellström KE, Hellström I, Greenberg P.
    J Immunol; 1991 May 01; 146(9):3235-41. PubMed ID: 1707934
    [Abstract] [Full Text] [Related]

  • 17. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V, Stirnemann K, Robert B, Luescher I, Filleron T, Corradin G, Mach JP, Donda A.
    Clin Cancer Res; 2006 Dec 15; 12(24):7422-30. PubMed ID: 17189415
    [Abstract] [Full Text] [Related]

  • 18. Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells.
    Nitta T, Yagita H, Azuma T, Sato K, Okumura K.
    Eur J Immunol; 1989 Aug 15; 19(8):1437-41. PubMed ID: 2528460
    [Abstract] [Full Text] [Related]

  • 19. Surface immunoglobulins are involved in the interaction of protein A with human B cells and in the triggering of B cell proliferation induced by protein A-containing Staphylococcus aureus.
    Romagnani S, Giudizi MG, Biagiotti R, Almerigogna F, Maggi E, Del Prete G, Ricci M.
    J Immunol; 1981 Oct 15; 127(4):1307-13. PubMed ID: 6974188
    [Abstract] [Full Text] [Related]

  • 20. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
    Belani R, Weiner GJ.
    J Hematother; 1995 Oct 15; 4(5):395-402. PubMed ID: 8581375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.